Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy

British Journal of Ophthalmology

Volumn 92, Issue 11, 2008, Pages 1498-1502

  Konstas, A G P ^a   Mikropoulos, D ^a   Dimopoulos, A T ^a   Moumtzis, G ^a   Nelson, L A ^b   Stewart, W C ^c,d,e  

^a Glaucoma Unit   (Greece)

^b Charleston Research Company LLC   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d University of South Carolina   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PLACEBO;

ABNORMAL SENSATION; ADULT; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EVENING DOSAGE; EYE BURNING; EYE DISCOMFORT; EYE IRRITATION; EYE PAIN; EYE STINGING; FEMALE; FOREIGN BODY SENSATION; HUMAN; INTRAOCULAR PRESSURE; MALE; MONOTHERAPY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STINGING SENSATION; TREATMENT DURATION; WATERY EYE; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 55449088607     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.145219     Document Type: Article

References (26)

1. Smith SL, Pruitt CA, Sine CS, et al. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1999;77:189-92.
2. Aim A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-52.
3. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
4. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
5. Nasser QJ, Stewart WC. Glaucoma treatment and diagnostic trends. Rev Ophthalmol 2006;13:87-93.
6. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-8.
7. Konstas AG, Papapanos P, Tersis I, et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003;110:1357-60.
8. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22.
9. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9.
10. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902.
11. Book SA. Essentials of statistics. New York: McGraw-Hill, 1978:117-22, 205-15.
12. Konstas AG, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128:15-20.
13. Mundorf TK, Cate EA, Sine CS, et al. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther 1998;14:129-35.
14. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh) 1987;65:618-21.
15. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131:631-5.
16. Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw Hill, 1956:63-7.
17. Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276-82.
18. Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 2004;18:1264-9.
19. Strohmaier K, Snyder E, Dubiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998;105:1936-44.
20. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22.
21. Pfeiffer N, German Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with IST individual components in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41(Suppl):754S.
22. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1999;106(Suppl):17-24S.
23. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999;106:10-16.
24. Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye 2004;18:1264-9.
25. Shin DH, Feldman RM, Sheu W-P. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276-82.
26. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003;12:480-5.